-
Janssen Biotech, Inc. v. Celltrion Healthcare Co., Ltd. et al DC CAFC
- 1:17-cv-11008
- D. Mass.
- Judge: Mark L. Wolf
- Filed: 05/31/2017
- Closed: 07/31/2018
- Latest Docket Entry: 04/13/2020
- PACER
- Docket updated daily
1
Plaintiff
3
Defendants
4
Accused
Products
1
Patent-in-Suit
427
Days in
Litigation
-
Janssen Biotech, Inc. v. Celltrion Healthcare Co., Ltd. et al DC CAFC
- 1:17-cv-11008
- D. Mass.
- Judge: Mark L. Wolf
- Filed: 05/31/2017
- Closed: 07/31/2018
- Latest Docket Entry: 04/13/2020
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Assigned Judge
Outcome Summary
- Patent Information
-
Infringement
Celltrion Healthcare Company Limited
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| biosimilar infliximab product | US 7,598,083 B2 | All Asserted Claims |
No infringement
Entry 393
|
Celltrion Incorporated
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| biosimilar infliximab product | US 7,598,083 B2 | All Asserted Claims |
No infringement
Entry 393
|
Hospira Incorporated
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| biosimilar infliximab product | US 7,598,083 B2 | All Asserted Claims |
No infringement
Entry 393
|
